Drugs / Terpinen-4-ol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01647217 | Feb 2014 → Jun 2015 | blepharitis | BioTissue Holdings, Inc | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04441528 | Nov 2018 → Nov 2019 | blepharitis | Istanbul University - Cerrahpasa | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | terpinen-4-ol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04441528 ↗ |
| Known as | T4O | “terpinen-4-ol (T4O), the most active ingredient of tea tree oil (TTO)” NCT01647217 ↗ |
| Modality | Small molecule | — CHEMBL2287509 ↗ |
| Route | Topical | “The lid wipes will be applied on the eyelids” NCT04441528 ↗ |